论文部分内容阅读
目的 观察第三代β受体阻滞剂卡维地洛(枢衡)对心力衰竭的临床疗效。方法 选取患者72例,其 中男性40例,女性32例,年龄31～72岁。心功能(NYHA)Ⅱ级28例,Ⅲ级32例,Ⅳ12例,将入选病人分成2组: 对照组、实验组。对照组在常规治疗(选用血管紧张素转换酶抑制剂、地高辛、利尿剂)的基础上加用安慰剂;实验 组在常规治疗的基础上加卡维地洛;治疗3个月观察其疗效。结果 实验组显效48.7%,有效38.5%,总有效率 87.2%。结论 实验组明显优于对照组,卡维地洛对心力衰竭治疗明显获益。
Objective To observe the clinical efficacy of the third generation β-blocker carvedilol (Hublot) in patients with heart failure. Methods 72 patients were selected, including 40 males and 32 females, aged 31 to 72 years. Heart function (NYHA) Ⅱ grade 28 cases, Ⅲ grade 32 cases, Ⅳ 12 cases, the selected patients were divided into two groups: control group, experimental group. The control group received placebo on the basis of conventional treatment (angiotensin converting enzyme inhibitor, digoxin and diuretic). The experimental group received carvedilol on the basis of routine treatment. The patients in the control group were observed for 3 months Efficacy. Results The experimental group markedly effective 48.7%, effective 38.5%, the total effective rate 87.2%. Conclusion The experimental group was significantly better than the control group, and carvedilol benefited the treatment of heart failure.